Actively Recruiting
Study of Nicotinamide Mononucleotide NMN to Improve IVF and ICSI Pregnancy Outcomes in Women Aged 20 to 40 with Reduced Ovarian Reserve
Led by Peking University Third Hospital · Updated on 2024-05-23
200
Participants Needed
1
Research Sites
52 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the effect of nicotinamide mononucleotide NMN on women aged 20 to 40 years with diminished ovarian reserve DOR undergoing IVF or ICSI-ET. This study aims to understand how NMN influences pregnancy outcomes, including clinical pregnancy rates, in this group. The trial is a randomized, double-blind, placebo-controlled clinical trial sponsored by Peking University Third Hospital. Participants are randomly assigned to one of two groups one receiving NMN capsules at a total dose of 600 mg per day for 2 to 5 months, and the other receiving placebo capsules without NMN for the same duration. The study compares these interventions to assess their impact on IVFICSI-ET outcomes. Treatment duration and follow-up periods are carefully monitored. During the study, participants will undergo assessments including hormone levels such as AMH and FSH, follicle counts, embryo culture outcomes, and metabolic indicators within three months after treatment. Pregnancy-related outcomes like biochemical pregnancy rate, live birth rate, abortion rate, pregnancy complications, and newborn conditions will be tracked for up to one year after treatment. The primary outcome measured is the clinical pregnancy rate over an average of two years. Participants must attend outpatient monitoring throughout the study period.
CONDITIONS
Brief Title
The Effeciency of NMN in Improving IVF/ICSI-ET Pregnancy Outcomes in Patients With DOR
Research Team
M
Mengyu Liu, PhD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here